Vyvgart Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of autoimmune disease mechanisms, approval of novel biologic therapies, increasing diagnosis rates of gMG, expansion of specialty neurology care, availability of advanced antibody therapies.

The growth in the forecast period can be attributed to expansion of indications beyond gMG, growing adoption of precision immunology treatments, increasing investments in autoimmune biologics, rising demand for long-term disease control options, development of next-generation fcrn inhibitors. Major trends in the forecast period include expanding adoption of fcrn inhibitor therapies, rising focus on targeted autoimmune disease treatments, increasing clinical use of antibody reduction mechanisms, growing demand for personalized immunotherapy solutions, enhanced emphasis on long-term disease management.

The rising prevalence of autoimmune diseases is expected to drive growth in the Vyvgart market. Autoimmune diseases occur when the body’s immune system mistakenly attacks healthy cells and tissues, treating them as foreign or harmful. This rise is attributed to genetic predisposition, environmental factors, infections, and lifestyle changes such as diet and increased chemical exposure. Vyvgart (efgartigimod alfa-fcab) is used to treat autoimmune diseases, particularly generalized myasthenia gravis (gMG), by targeting the neonatal Fc receptor (FcRn) to reduce pathogenic antibodies that contribute to disease progression. For example, in August 2024, the Myasthenia Gravis Foundation of America, a US-based organization, reported that gMG affects approximately 150 to 200 individuals per million worldwide, with around 37 per 100,000 people affected in the United States. Therefore, the increasing prevalence of autoimmune diseases is driving the Vyvgart market.

A key trend in the Vyvgart market is the focus on obtaining regulatory approvals to strengthen its competitive position. Regulatory approvals validate the safety and efficacy of Vyvgart, improve market access, and build confidence among physicians and patients. For instance, in March 2024, argenx, a Netherlands-based immunology company, announced that Vyvgart (efgartigimod alfa) received approval in Japan for adults with primary immune thrombocytopenia (ITP). This approval, granted by Japan’s Ministry of Health, Labour and Welfare, is the first global endorsement of Vyvgart specifically for ITP, expanding its use beyond gMG, for which it is already approved in regions including the United States and Europe. Vyvgart is a human IgG1 antibody fragment that targets FcRn, reducing circulating IgG autoantibodies and providing an effective therapy option for patients with autoimmune conditions who previously had limited treatment choices.

In September 2025, FUJIFILM Holdings Corporation, a Japan-based contract development and manufacturing organization, partnered with argenx to expand its global manufacturing collaboration. This partnership aims to increase argenx’s production capacity, strengthen its U.S. supply chain, and ensure consistent global access to Vyvgart therapies. Argenx SE, based in the Netherlands, is the company behind Vyvgart.

Major companies operating in the vyvgart market are Argenx SE.

North America was the largest region in the vyvgart market in 2025. The regions covered in the vyvgart market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vyvgart market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the vyvgart market by increasing costs associated with imported biologic manufacturing inputs, specialized filtration systems, cold-chain logistics, and packaging materials used in monoclonal antibody production. North America and Europe are most affected due to dependence on globally sourced bioprocessing components, while Asia-Pacific faces cost pressure on contract manufacturing services. These tariffs contribute to higher production and distribution expenses, influencing pricing strategies and reimbursement negotiations. However, they are also encouraging localized biologics manufacturing, regional supply chain diversification, and investments in domestic biopharmaceutical production infrastructure.

The vyvgart market research report is one of a series of new reports that provides vyvgart market statistics, including vyvgart industry global market size, regional shares, competitors with a vyvgart market share, detailed vyvgart market segments, market trends and opportunities, and any further data you may need to thrive in the vyvgart industry. This vyvgart market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vyvgart (efgartigimod alfa-fcab) is a monoclonal antibody therapy used to treat autoimmune disorders, primarily generalized myasthenia gravis (gMG). It functions by inhibiting the neonatal Fc receptor (FcRn), which reduces pathogenic antibodies in the bloodstream, helping to improve muscle strength and reduce fatigue associated with the disease.

The main indications for Vyvgart are generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Generalized myasthenia gravis is a chronic autoimmune neuromuscular disorder that impairs communication between nerves and muscles, leading to muscle weakness. Vyvgart is administered to adults and geriatric patients, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The vyvgart market consists of sales of intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.